![MDD](https://www.adcreviews.com/wp-content/uploads/2022/08/MDD-300x200.jpeg)
FDA approves first antagonist for adult major depressive disorder
On August 19, Axsome Therapeutics announced that the US FDA approved Auvelity (dextromethorphan 45mg + bupropion 105mg) compound sustained-release tablets for the treatment of adult
On August 19, Axsome Therapeutics announced that the US FDA approved Auvelity (dextromethorphan 45mg + bupropion 105mg) compound sustained-release tablets for the treatment of adult